PEITC triggers multiple forms of cell death by GSH-iron-ROS regulation in K7M2 murine osteosarcoma cells

• 作者: Chen-xiao Zhen Huan-huan Lv Jun-yu Liu Peng Shang
• 来源期刊: 中国药理学报（英文版）
• 关键词: osteosarcoma PEITC redox system iron metabolism MAPK signaling pathway cell death
• 年，卷（期）: 2020,（8）
• 页码范围: 1119-1132
• 页数: 14页
• 语种: 英文

摘要

Phenethyl isothiocyanate (PEITC) is an isothiocyanate that largely exists in cruciferous vegetables and exhibits chemopreventive and chemotherapeutic potential against various cancers.However,it is little known about the molecular mechanisms of its antitumor action against osteosarcoma,which is the second highest cause of cancer-related death in children and adolescents.In this study,we investigated the effects of PEITC on K7M2 murine osteosarcoma both in vitro and in vivo.We found that treatment with PEITC dose-dependently inhibited the viability of K7M2 murine osteosarcoma cells with an ICs0 value of 33.49 μM at 24 h.PEITC (1,15,30 μM) dose-dependently inhibited the cell proliferation,caused G2/M cell cycle arrest,depleted glutathione (GSH),generated reactive oxygen species (ROS),altered iron metabolism,and triggered multiple forms of cell death,namely ferroptosis,apoptosis,and autophagy in K7M2 cells.We further revealed that PEITC treatment activated MAPK signaling pathway,and ROS generation was a major cause of PEITC-induced cell death.In a syngeneic orthotopic osteosarcoma mouse model,administration of PEITC (30,60 mg/kg every day,ig,for 24 days) significantly inhibited the tumor growth,but higher dose of PEITC (90 mg/kg every day) compromised its anti-osteosarcoma effect.Histological examination showed that multiple cell death processes were initiated,iron metabolism was altered and MAPK signaling pathway was activated in the tumor tissues.In conclusion,we demonstrate that PEITC induces ferroptosis,autophagy,and apoptosis in K7M2 osteosarcoma cells by activating the ROS-related MAPK signaling pathway.PEITC has promising anti-osteosarcoma activity.This study sheds light on the redox signaling-based chemotherapeutics for cancers.